logo

Insmed Inc (INSM)



Trade INSM now with
  Date
  Headline
2/25/2021 8:24:28 AM Insmed Inc Q4 Net Loss $102.2 Mln Vs. Net Loss $53.0 Mln Last Year
2/19/2021 7:31:38 AM Insmed Announces Topline Results From Phase 1 Study Of Treprostinil Palmitil Inhalation Powder
1/4/2021 8:54:53 AM Insmed Initiates Frontline Clinical Trial Program For ARIKAYCE In Patients With MAC Lung Disease
12/2/2020 8:12:01 AM Insmed Initiates Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis
11/13/2020 8:05:29 AM Insmed Receives Priority Medicines Designation From EMA For Brensocatib In Patients With NCFBE
10/28/2020 7:44:59 AM Insmed Says European Commission Grants Marketing Authorization For ARIKAYCE® Liposomal 590 Mg Nebuliser Dispersion
10/2/2020 8:05:35 AM Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9/4/2020 8:01:24 AM Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
8/6/2020 7:43:33 AM Insmed Q2 Net Loss $61.9 Mln Or $0.64/shr Vs. Net Loss $66.5 Mln Or $0.81/shr Last Year
7/24/2020 7:54:41 AM Insmed Receives Positive CHMP Opinion For ARIKAYCE Liposomal 590 Mg Nebuliser Dispersion
7/7/2020 8:06:35 AM Insmed : NTM Treatment Guidelines Recommend ARIKAYCE For Treatment Of Patients With Refractory MAC Lung Disease
6/24/2020 4:03:49 PM Insmed: Brensocatib Reduces Time To First Pulmonary Exacerbation And Reduces Rate Of Exacerbations Versus Placebo
6/8/2020 8:07:13 AM Insmed Gets FDA Breakthrough Therapy Designation For Brensocatib In Patients With Non-Cystic Fibrosis Bronchiectasis
5/20/2020 9:31:13 AM Insmed To Present New Data From Phase 2 WILLOW Study Of Brensocatib